» Articles » PMID: 30452959

Mathematical Modeling of Hepatitis C Virus (HCV) Prevention Among People Who Inject Drugs: A Review of the Literature and Insights for Elimination Strategies

Overview
Journal J Theor Biol
Publisher Elsevier
Specialty Biology
Date 2018 Nov 20
PMID 30452959
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

In 2016, the World Health Organization issued global elimination targets for hepatitis C virus (HCV), including an 80% reduction in HCV incidence by 2030. The vast majority of new HCV infections occur among people who inject drugs (PWID), and as such elimination strategies require particular focus on this population. As governments urgently require guidance on how to achieve elimination among PWID, mathematical modeling can provide critical information on the level and targeting of intervention are required. In this paper we review the epidemic modeling literature on HCV transmission and prevention among PWID, highlight main differences in mathematical formulation, and discuss key insights provided by these models in terms of achieving WHO elimination targets among PWID. Overall, the vast majority of modeling studies utilized a deterministic compartmental susceptible-infected-susceptible structure, with select studies utilizing individual-based network transmission models. In general, these studies found that harm reduction alone is unlikely to achieve elimination targets among PWID. However, modeling indicates elimination is achievable in a wide variety of epidemic settings with harm reduction scale-up combined with modest levels of HCV treatment for PWID. Unfortunately, current levels of testing and treatment are generally insufficient to achieve elimination in most settings, and require further scale-up. Additionally, network-based treatment strategies as well as prison-based treatment and harm reduction provision could provide important additional population benefits. Overall, epidemic modeling has and continues to play a critical role in informing HCV elimination strategies worldwide.

Citing Articles

Potential impact of curative and preventive interventions toward hepatitis C elimination in people who inject drugs-A network modeling study.

Zhu L, Thompson W, Hagan L, Randall L, Rudolph A, Young A Int J Drug Policy. 2024; 130:104539.

PMID: 39033645 PMC: 11347083. DOI: 10.1016/j.drugpo.2024.104539.


Network-based strategies to combat HCV: Examining social and spatial drivers of transmission among PWID in New Delhi.

Clipman S, Mehta S, Mohapatra S, Srikrishnan A, Zook K, Kumar M J Viral Hepat. 2024; 31(9):535-543.

PMID: 38837275 PMC: 11480898. DOI: 10.1111/jvh.13960.


Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.

Petkeviciene J, Voeller A, ciupkeviciene E, Razavi-Shearer D, Liakina V, Jancoriene L BMC Public Health. 2024; 24(1):1055.

PMID: 38622549 PMC: 11020450. DOI: 10.1186/s12889-024-18470-5.


Impact of voluntary testing on infectious disease epidemiology: A game theoretic approach.

Pepiot A, Supervie V, Breban R PLoS One. 2023; 18(11):e0293968.

PMID: 37934734 PMC: 10629633. DOI: 10.1371/journal.pone.0293968.


Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.

Laniece Delaunay C, Klein M, Godin A, Cox J, Kronfli N, Lebouche B Int J Drug Policy. 2023; 116:104026.

PMID: 37075626 PMC: 10080278. DOI: 10.1016/j.drugpo.2023.104026.


References
1.
Mather D, Crofts N . A computer model of the spread of hepatitis C virus among injecting drug users. Eur J Epidemiol. 1999; 15(1):5-10. DOI: 10.1023/a:1007548307196. View

2.
Murray J, Law M, Gao Z, Kaldor J . The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol. 2003; 32(5):708-14. DOI: 10.1093/ije/dyg102. View

3.
Esposito N, Rossi C . A nested-epidemic model for the spread of hepatitis C among injecting drug users. Math Biosci. 2004; 188:29-45. DOI: 10.1016/j.mbs.2003.11.001. View

4.
Shepard C, Finelli L, Alter M . Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5(9):558-67. DOI: 10.1016/S1473-3099(05)70216-4. View

5.
Fazel S, Bains P, Doll H . Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006; 101(2):181-91. DOI: 10.1111/j.1360-0443.2006.01316.x. View